CELLphenomics and Charles River announce agreement, expanding 3D in vitro services for cancer therapy drug screening
Berlin, Germany and Wilmington, Mass., Jan. 9, 2024 – CELLphenomics and Charles River Laboratories International, Inc. (NYSE: CRL) announced an agreement, that provides Charles River clients with access to CELLphenomics’ proprietary 3D tumor model platform, PD3D®, which will expand Charles River’s 3D in vitro testing services to further optimize oncological approaches for its clients. CELLphenomics’ core competence is the […]
CELLphenomics, KYAN Technologies and Alentis Therapeutics join forces
Berlin, Singapore, Allschwil 9-29-2023 CELLphenomics and KYAN Technologies, a vanguard combinatory drug development solutions provider, are thrilled to announce a strategic partnership with Alentis Therapeutics, a clinical-stage biopharmaceutical company developing breakthrough treatments for Claudin-1 positive tumours and organ fibrosis. This partnership aims to accelerate research into Claudin-1 expression using innovative patient-derived 3D (PD3D®) cell culture […]
Samantha Forbrig
Dr. Samantha Forbrig obtained her Diploma in Human Biology from the University of Greifswald before relocating to the Department of Gastroenterology at Charité Berlin for her PhD thesis. Since then her work and research focused on cancer and its targeted diagnosis and therapy. Samantha is well experienced with various primary 2D and 3D cell culture techniques, the establishment of […]
Manuela Regenbrecht
Manuela Regenbrecht is the director of medical affairs at CELLphenomics. She is a medical specialist in internal medicine, hematology and oncology. Born in Berlin, she studied medicine at the Charité Universitätsmedizin Berlin as a scholarship holder from the German Academic Scholarship Foundation. She spend part of the practical year in Nepal. She completed her subsequent residency […]
